Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
06/05/2026

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

…(Keytruda), a checkpoint inhibitor that targets the immune system. In total, the trial enrolled 107 patients following melanoma surgery to…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
06/05/2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

…this Phase 1/2 study had metastatic melanoma whose disease progressed after receiving standard checkpoint inhibitor therapies such as ipilimumab (Yervoy)…
Blog - Melanoma360
, 
Melanoma Research

Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)

…(Keytruda), a checkpoint inhibitor that targets the immune system. In total, the trial enrolled 107 patients following melanoma surgery to…
Featured image for “Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)”
Blog - Melanoma360
, 
Melanoma Research

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

…this Phase 1/2 study had metastatic melanoma whose disease progressed after receiving standard checkpoint inhibitor therapies such as ipilimumab (Yervoy)…
Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Blog - Melanoma360
, 
Melanoma Research

Recent Posts

Featured image for “Women in Melanoma: A New Chapter in Europe”
Aug. 31, 2026

Women in Melanoma: A New Chapter in Europe

Featured image for “The Legal & Financial Side of a Diagnosis: What No One Tells You”
Aug. 31, 2026

The Legal & Financial Side of a Diagnosis: What No One Tells You

Featured image for “Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma”
Aug. 19, 2026

Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma

Featured image for “RP1 Approved: A Long Road to a New Option for Patients”
Aug. 07, 2026

RP1 Approved: A Long Road to a New Option for Patients

Featured image for “FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma”
Aug. 06, 2026

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

Filter by Tag